Home Ingredients Cardiomega™
CardiovascularAntioxidantMetabolic Health

Cardiomega™

Evidence Level
Limited
2 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

Cardiomega™ is a Natreon-branded cardiovascular formulation built around Capros® standardized amla (Phyllanthus emblica) extract — a galloyl-tannin-rich concentrate with emblicanin A and B — combined with supporting botanicals for healthy lipid metabolism and oxidative balance. The direct branded clinical literature for the finished Cardiomega™ blend is limited; most of the supporting evidence comes from human RCTs on its anchor ingredient, Capros®/Amlamax-class amla extract, which has been shown to improve endothelial function, reduce LDL oxidation, lower hsCRP, and support a healthier lipid profile in overweight adults and people with type 2 diabetes or metabolic syndrome.

Studied Dose Capros® amla extract is the anchor component; human cardiovascular trials of the amla extract used 250–500 mg twice daily for 12 weeks. Finished-product Cardiomega™ dose: follow label directions.
Active Compound Capros® standardized Phyllanthus emblica (amla) extract — galloyl tannins, emblicanin A and B, gallic acid — plus supporting cardiovascular botanicals in the Cardiomega™ blend

Benefits

Healthy lipid profile support

Human trials of Capros®-class standardized amla extract — the anchor component of Cardiomega™ — show meaningful reductions in calculated LDL cholesterol and the total-cholesterol-to-HDL ratio in overweight and metabolically at-risk adults, helping support a cardiovascular-friendly lipid profile over 12 weeks of daily use.

Supported by Trial 1, Trial 2

Endothelial function and vascular tone

Standardized amla extract supports endothelial function as measured by digital volume pulse reflection index in adults with type 2 diabetes and metabolic syndrome. The improvement is consistent with better nitric oxide signaling and may help maintain healthy arterial responsiveness.

Supported by Trial 2, Trial 1

Antioxidant defense for cardiovascular tissues

Amla's galloyl tannins and slow-release vitamin C help reduce oxidative damage to LDL particles and vascular cells — an upstream factor in atherosclerotic plaque development — supporting overall cardiovascular antioxidant balance.

Supported by Trial 1

Cardiovascular inflammation balance

Standardized amla extract has been shown to lower hsCRP and other inflammatory markers in adults with elevated cardiometabolic risk, helping support a healthy inflammatory state alongside diet and lifestyle measures.

Supported by Trial 1, Trial 2

Mechanism of action

1

LDL oxidation defense via galloyl tannins

Emblicanin A and B and free gallic acid scavenge reactive oxygen species and quench lipid peroxyl radicals, reducing oxidative modification of LDL particles — a key initiating event in atherogenesis.

2

Endothelial NO support

Amla polyphenols help preserve endothelial nitric oxide bioavailability by lowering local oxidative stress and quenching superoxide that would otherwise react with NO, supporting flow-mediated dilation and vascular reactivity.

3

NF-κB and hsCRP modulation

Gallic acid and ellagitannins downregulate NF-κB-driven cytokine transcription in vascular and hepatic tissues, helping reduce systemic inflammatory load reflected in hsCRP and related markers.

Clinical trials

1
Capros® Amla Extract for CV Risk in Overweight Adults

12-week supplementation trial with standardized P. emblica extract (Capros®, 500 mg twice daily) in overweight and class-1 obese US adults. Measured calculated LDL cholesterol, total cholesterol/HDL ratio, hsCRP, and platelet aggregation.

Overweight and class-1 obese adults (BMI 25–35).

Standardized amla extract significantly reduced calculated LDL cholesterol, total cholesterol/HDL ratio, and hsCRP. ADP- and collagen-induced platelet aggregation were significantly decreased after 12 weeks. Supports use of the Capros® amla anchor component for healthy lipid and vascular endpoints.

2
Amla Extract for Endothelial Function in T2D

Randomized, double-blind, placebo-controlled trial comparing standardized P. emblica extract (250 or 500 mg twice daily) with atorvastatin 10 mg and placebo over 12 weeks in 80 adults with type 2 diabetes. Outcomes: endothelial function (reflection index), malondialdehyde, glutathione, hsCRP, lipid profile, HbA1c.

80 adults with type 2 diabetes. 12-week intervention.

All active arms significantly improved endothelial reflection index versus placebo. The higher amla dose produced reductions in malondialdehyde and hsCRP comparable to atorvastatin 10 mg, along with improvements in lipid profile and HbA1c. Well-tolerated across groups.

Side effects and drug interactions

Common Potential side effects

Mild gastrointestinal upset, loose stools, or acidity at higher amla doses.
Rare allergic reaction in individuals sensitive to Phyllanthus or related plants.
May lower blood glucose modestly; monitor in people with diabetes.
May lower LDL and blood pressure modestly; monitor in those on therapy.

Important Drug interactions

Antiplatelets and anticoagulants (warfarin, aspirin, clopidogrel) — amla may further reduce platelet aggregation; monitor.
Antihyperglycemics (metformin, sulfonylureas, insulin) — additive glucose-lowering; monitor blood sugar.
Statins and other lipid-lowering drugs — overlapping LDL and oxidative effects; monitor lipids.
Antihypertensives — possible additive blood-pressure reduction; monitor BP.

More Cardiovascular Ingredients

Cardiovascular
Niacin
Niacin, or vitamin B3, is a vital nutrient that supports energy production by serving as a…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cardiovascular
Potassium
Potassium is the most abundant intracellular cation in the human body and an essential min…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…

Explore Other Ingredients

Athletic Performance
L-Citrulline
L-Citrulline is a naturally occurring amino acid that supports nitric oxide production, he…
Cardiovascular
Beetroot
Beetroot is a rich dietary source of inorganic nitrate, which the body converts to nitric…
Antioxidant
Curcumin/Turmeric
Curcumin, the primary bioactive compound in turmeric (Curcuma longa), is commonly suppleme…

Frequently asked questions about Cardiomega™

What is the recommended dosage of Cardiomega™?

The clinically studied dose for Cardiomega™ is Capros® amla extract is the anchor component; human cardiovascular trials of the amla extract used 250–500 mg twice daily for 12 weeks. Finished-product Cardiomega™ dose: follow label directions.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Cardiomega™ used for?

Cardiomega™ is studied for healthy lipid profile support, endothelial function and vascular tone, antioxidant defense for cardiovascular tissues. Human trials of Capros®-class standardized amla extract — the anchor component of Cardiomega™ — show meaningful reductions in calculated LDL cholesterol and the total-cholesterol-to-HDL ratio in overweight and metabolically at-risk adults, helping su…

Are there side effects from taking Cardiomega™?

Reported potential side effects may include: Mild gastrointestinal upset, loose stools, or acidity at higher amla doses. Rare allergic reaction in individuals sensitive to Phyllanthus or related plants. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Cardiomega™ interact with medications?

Known drug interactions may include: Antiplatelets and anticoagulants (warfarin, aspirin, clopidogrel) — amla may further reduce platelet aggregation; monitor. Antihyperglycemics (metformin, sulfonylureas, insulin) — additive glucose-lowering; monitor blood sugar. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Cardiomega™ good for cardiovascular?

Yes, Cardiomega™ is researched for Cardiovascular support. Human trials of Capros®-class standardized amla extract — the anchor component of Cardiomega™ — show meaningful reductions in calculated LDL cholesterol and the total-cholesterol-to-HDL ratio in overweight and metabolically at-risk adults, helping support a cardiovascular-friendl…

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Khanna S, Das A, Spieldenner J, Rink C, Roy S. Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults. J Med Food. 2015;18(4):415-20. doi: 10.1089/jmf.2014.0178.PubMedUsed to support: Standardized Phyllanthus emblica extract (CAPROS®, 500 mg twice daily for 12 weeks) significantly reduced calculated LDL cholesterol, total cholesterol/HDL ratio, and hsCRP, and significantly decreased ADP- and collagen-induced platelet aggregation in overweight/class-1 obese US adults. Backs the Cardiomega anchor (Capros® amla) lipid and platelet claims.
  2. Usharani P, Fatima N, Muralidhar N. Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study. Diabetes Metab Syndr Obes. 2013;6:275-84. doi: 10.2147/DMSO.S46341.PubMedUsed to support: 80 T2D adults; 12 weeks of standardized P. emblica extract at 250 or 500 mg twice daily significantly improved endothelial reflection index, reduced malondialdehyde, and lowered hsCRP versus placebo, with the 500 mg dose comparable to atorvastatin 10 mg. Supports Cardiomega's endothelial and antioxidant claims via the amla anchor.